NuVasive, Inc. (NUVA)
(Delayed Data from NSDQ)
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
NuVasive (NUVA) Boosts Cervical Portfolio With New Buyout
by Zacks Equity Research
NuVasive (NUVA) expands comprehensive portfolio of C360 with the addition of Simplify Disc.
NuVasive's (NUVA) Q4 Earnings Top Estimates, Margin Declines
by Zacks Equity Research
NuVasive (NUVA) registers strong international performance in Q4 along with continued adoption of advanced material science implants in the U.S. Spinal Hardware business.
Earnings Preview: NuVasive (NUVA) Q4 Earnings Expected to Decline
by Zacks Equity Research
NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to NuVasive (NUVA) Stock for Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently launched products as well as potential in its U.S. Surgical Support business.
NuVasive (NUVA) Focuses on Cervical Spine Portfolio Expansion
by Zacks Equity Research
The ACP system within NuVasive (NUVA) C360 is targeted to reduce common postoperative complications such as dysphagia, malalignment and adjacent level ossification.
NuVasive (NUVA) Launches C360 Portfolio for Cervical Spine
by Zacks Equity Research
The ACP system within NuVasive's (NUVA) C360 portfolio is targeted to reduce common postoperative complications.
NuVasive (NUVA) Q3 Earnings Beat, Gross Margin Declines
by Zacks Equity Research
NuVasive (NUVA) registers strong international performance in Q3 along with several spinal hardware product lines growing at high single digits or more.
NuVasive (NUVA) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 100.00% and 14.09%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate NuVasive (NUVA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to NuVasive (NUVA) Stock Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as potential in its U.S. Surgical Support business.
NUVA or SRDX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NUVA vs. SRDX: Which Stock Is the Better Value Option?
NuVasive's (NUVA) MaXcess Retractor Study Results Positive
by Zacks Equity Research
NuVasive's (NUVA) MaXcess retractor's ability to perform lateral surgery in various approaches, including prone position, is validated by favorable study outcome.
NuVasive Banks on Product Launches Amid Procedural Volume Loss
by Zacks Equity Research
NuVasive (NUVA) is leaving no stone unturned to capture the fast-growing spine market.
Why Is NuVasive (NUVA) Up 1.9% Since Last Earnings Report?
by Zacks Equity Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to NuVasive (NUVA) Stock Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as potential in its U.S. Surgical Support business.
NuVasive's (NUVA) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
NuVasive's (NUVA) operating segments experienced slowdown in second-quarter volumes due to the coronavirus pandemic.
NuVasive (NUVA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 18.37% and -0.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will NuVasive (NUVA) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
NuVasive (NUVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NuVasive (NUVA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
NuVasive (NUVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NuVasive Launches Reline 3D for Pediatric Patients Globally
by Zacks Equity Research
Other than Reline 3D, NuVasive's (NUVA) Reline System portfolio has products like Reline Open, Reline MAS, Reline Trauma and Reline Small Stature.
Here's Why You Should Hold on to NuVasive (NUVA) Stock Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as solid international business.
NuVasive (NUVA) Up 6.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for May 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
NuVasive's (NUVA) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
NuVasive's (NUVA) operating segments experience slowdown in first-quarter volumes due to the coronavirus pandemic.
NuVasive (NUVA) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 37.14% and 0.05%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?